DSGN

Design Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, focused on pioneering innovative therapies for degenerative disorders associated with nucleotide repeat expansions, such as Friedreich's ataxia. The company is advancing a proprietary pipeline of small-molecule drug candidates aimed at targeting the genetic underpinnings of these diseases, with the goal of restoring normal cellular function and improving patient outcomes. Committed to robust research and clinical development, Design Therapeutics is strategically positioned to address significant unmet medical needs in underserved patient populations, reinforcing its potential as a leader in the biopharmaceutical sector.